Shree Patel
University of Illinois at Chicago
10 Papers
Shree Patel is an academic researcher from University of Illinois at Chicago. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 6 publications.
Chat about Author
Papers
Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia.
Mark Biagi,D Lamm,Kevin A. Meyer,A Vialichka,M Jurkovic,Shree Patel,R E Mendes,Zackery P Bulman,Eric Wenzler +8 more
TL;DR: Aztreonam-avibactam is the most promising BLI-combination against multidrug resistant Stenotrophomonas maltophilia as discussed by the authors, however, it has not been explored molecular mechanisms for reduced susceptibility to these combinations.
32
Development of the Lung Transplant Frailty Scale (LT-FS).
Jonathan P. Singer,Jason D. Christie,Joshua M. Diamond,Michaela R. Anderson,Luke A Benvenuto,Ying Gao,Selim M. Arcasoy,David J. Lederer,Daniel R Calabrese,Ping Wang,Steven R. Hays,Jasleen Kukreja,Aida Venado,Nicholas A. Kolaitis,Lorriana E Leard L,Rupal J. Shah,Mary Ellen Kleinhenz,Jeffrey A. Golden,Legna Betancourt,Michelle Oyster,D. Zaleski,Joseph Adler,Laurel Kalman,P. Balar,Shree Patel,N. Medikonda,Brittany Koons,Michael A. Tevald,Kenneth E. Covinsky,John R. Greenland,Patti Katz +30 more
TL;DR: In this article , the authors developed a lung transplant frailty scale (LT-FS), which is a disease-specific physical frailty measure with face and construct validity that has superior predictive validity over established measures, such as short physical performance battery (SPPB), fried frailty phenotype (FFP), body composition, and serum biomarkers representative of putative frailty mechanisms.
16
The Significance and Impact of Screening Preservation Fluid Cultures in Renal Transplant Recipients.
TL;DR: This study suggests antimicrobial treatment for culture positive PF may not be necessary with pathogens that are common contaminants and of low virulence, and interventional studies are needed to validate this strategy.
8
Subphenotypes of frailty in lung transplant candidates.
Jonathan P. Singer,Carolyn S. Calfee,Kevin L. Delucchi,Joshua M. Diamond,Michaela R. Anderson,Luke A Benvenuto,Ying Gao,Ping Wang,Selim M. Arcasoy,David J. Lederer,Steven R. Hays,Jasleen Kukreja,Aida Venado,Nicholas A. Kolaitis,Lorianna E. Leard L,Rupal J. Shah,Mary Ellen Kleinhenz,Jeffrey A. Golden,Legna Betancourt,Michelle Oyster,Melanie C Brown,D. Zaleski,N. Medikonda,Laurel Kalman,P. Balar,Shree Patel,Daniel R Calabrese,John R. Greenland,Jason D. Christie +28 more
TL;DR: In this paper , the Short Physical Performance Battery, body composition, and serum biomarkers reflecting causes of frailty were used to identify biological frailty subphenotypes in lung transplant candidates.
8
A randomized, open‐label pharmacokinetic trial of tacrolimus extended‐release dosing in obese de novo kidney transplant recipients
Natalia M. Jasiak‐Panek,Eric Wenzler,Shree Patel,J. Thielke,Kristin Progar,Shitalben R. Patel,Shane Brandt,Yi‐jen Huang,Enrico Benedetti,Patricia West-Thielke +9 more
TL;DR: The purpose of this study was to determine the best method of dosing TAC‐ER in obese renal transplant recipients.
4